Algerian Pharma & Healthcare: 5 Things to Know
With a healthcare system marked by both progress and difficulties due to the country’s economic overreliance on the oil and gas sector and its recent political instability, Algeria, is the…
Biopharm is an industrial and commercial group that invested in the pharmaceutical sector in the early 1990s and now has a production unit that meets international standards and a distribution network for wholesalers, processors and pharmacies.
Biopharm began by gradually adapting its organisational structure as a Group around its various businesses:
– Drug production through Biopharm, which remains the core of the Group
– Wholesale distribution of pharmaceutical products through Biopharm Distribution
– Distribution to pharmacies through Biopure
– Medical promotion and information, through HHI (Human Health Information)
– Logistics for the pharmaceutical industry through Biopharm Logistic
In 2015, Biopharm finalized the creation of a joint venture with the Indian generic company Cipla to build a respiratory medicine factory. In 2012, they signed an industrial partnership with the British company AstraZeneca to establish a new production unit doubled by a distribution centre in the Algiers region.
Since 2013, Biopharm has been 49% owned by a consortium made up of the Financial Development Partners International (DPI) and Mediterrània Capital as well as the German development agency DEG.
In September 2016, with a market cap of DZD 31.5 billion (c. USD 290 million), Biopharm became the fifth company to enter Algeria’s stock market and accounts for 70% of the total Algiers stock exchange market cap.
With a healthcare system marked by both progress and difficulties due to the country’s economic overreliance on the oil and gas sector and its recent political instability, Algeria, is the…
Dr Anthony Y. Lauw, GM & Head of Human Pharma Northwest Africa at Boehringer Ingelheim, explains the operations of a cluster that has typically worked with local partners, but that…
A roundup of the latest news from pharma in the Middle East and Africa including China’s announcement that it will be prioritising Africa for access to its COVID-19 vaccine, UAE…
In the wake of a spate of television advertisements for dietary supplements claiming to offer solutions to the COVID-19 crisis, regular PharmaBoardroom contributor Yacine Sellam argues for the need for…
Below we present recent news from Algeria’s pharmaceutical industry, including the creation of a dedicated Ministry to boost the sector, changes to the advertising rules for dietary supplements, and local…
Yacine Sellam examines how pharmacists in Algeria can follow the lead of their US counterparts and play a greater role in patients’ diabetes management. Noncommunicable diseases are a growing…
Yacine Sellam, president of the Algerian Society for Regulatory Affairs & Pharmacoeconomics, looks at how European countries such as France and Belgium have countered medicine supply shortages and how Algeria…
Yacine Sellam, president of the Algerian Society for Regulatory Affairs & Pharmacoeconomics, examines Algeria’s recent issues around medicine shortages, its root causes, and the measure being taken to counter it.…
The Middle East and North Africa (MENA) region’s pharmaceutical market is projected to reach a value of around USD 60 billion by 2025 according to reporting from TradeArabia. The most…
Yacine Sellam, president of the Algerian Society for Regulatory Affairs & Pharmacoeconomics, outlines the progress made under Algeria’s National Cancer Plan and the steps that still need to be taken…
Adlane Soudani, general manager of Ipsen’s Algerian affiliate, lifts the lid on Ipsen’s ambitions for the local market, and the company’s parallel strategies to ramp up local production while simultaneously…
Ipsen’s Guillaume Freneuil gives his take on the importance of the Algerian market to the global group. If we are investing right now in Algeria it is because we…
See our Cookie Privacy Policy Here
